HHS invests in U.S. capacity to make COVID-19 molecular tests for providers
![COVID19 Testing Web Sized](/sites/default/files/styles/900x400/public/2020-03/banner-covid-testing-3.jpg?itok=RVA4TWjA)
The Department of Health and Human Services will use $650 million from the American Rescue Plan Act to expand U.S. capacity to manufacture rapid molecular tests for COVID-19, which hospitals and other health care providers use to diagnose COVID-19, screen patients before surgery and confirm at-home test results.
“By strengthening our ability to produce these tests in the United States, we will minimize our reliance on imports from overseas, and sustain robust long-term manufacturing throughout 2022,” HHS said. “The funding will also support purchasing raw materials and finished tests to increase our domestic supply of diagnostic tests.”
Related News Articles
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…